CORTCORTHealthcare · Biotechnology

CORT Stock Forecast: Corcept Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 17 Nov 2026
$70
+1.23% on the day

The 5 Wall Street analysts covering Corcept Therapeutics, Inc. hold a median 12-month price target of $164 — +134.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 16 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$7.7B
Ticker Nerd rank
75/ 100
Median analyst target
$164
Analysts covering
5
Revenue$256.1M+31.7% y/y
Operating income$41.3M
Net income$43.0M
Free cash flow$31.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.5%
1M
−36.4%
YTD
+101.4%
1Y
−6.7%
From 52W high
−43.3%
From 52W low
+117.9%
$32
$124
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CORT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Corcept Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 16 Nov 2026
75/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
96
Quality
86
Growth
83
Revisions
79
Momentum
62
Volatility
49
Issuance
40
Accruals
25
Size
18

Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (25): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CORT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CORT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200Jan 26Apr 26Jul 26Oct 26CORTHigh $173Median $164Low $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy0 Hold1 Sell
Low $50Median $164High $173

The green dot is the last close — the median target sits +134.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
4 Nov 2026Piper SandlerReiteratesOverweight$165 → $173
18 Sept 2026HC Wainwright & Co.ReiteratesBuy$165
18 Sept 2026HC Wainwright & Co.ReiteratesBuy—
30 July 2026Canaccord GenuityMaintainsBuy$150 → $161
30 July 2026Canaccord GenuityMaintainsBuy—
30 July 2026HC Wainwright & Co.MaintainsBuy$95 → $165
30 July 2026HC Wainwright & Co.MaintainsBuy—
30 July 2026Piper SandlerReiteratesOverweight—
30 July 2026Piper SandlerReiteratesOverweight$88 → $165
29 July 2026Canaccord GenuityMaintainsBuy—
29 July 2026Canaccord GenuityMaintainsBuy$135 → $150
27 July 2026Wolfe ResearchDowngradeUnderperform—
27 July 2026Wolfe ResearchDowngradeUnderperform$50
28 May 2026Canaccord GenuityMaintainsBuy$110 → $135
28 May 2026Canaccord GenuityMaintainsBuy—
28 May 2026HC Wainwright & Co.MaintainsBuy—
28 May 2026HC Wainwright & Co.MaintainsBuy$75 → $95
13 May 2026UBSUpgradeBuy—
4 May 2026HC Wainwright & Co.MaintainsBuy—
1 May 2026Piper SandlerMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CORT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CORT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Nov 2026, Corcept Therapeutics, Inc. returned −6.7% against +11.2% for the S&P 500, dividends included.

CORT vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Jan 26Apr 26Jul 26Oct 26CORTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CORT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+7.7%
Analysts raising
0
Analysts cutting
1
Fundamentals

Corcept Therapeutics, Inc. (CORT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
52.7×

Cheaper than 13% of US stocks

Price / sales
8.0×

Cheaper than 15% of US stocks

Price / book
9.2×

Cheaper than 9% of US stocks

EV / EBITDA
64.6×

Cheaper than 3% of US stocks

Growth & margins
Revenue growth (YoY)
64.0%

Higher than 89% of US stocks

Earnings growth (YoY)
544.6%

Higher than 96% of US stocks

Gross margin
98.4%

Higher than 99% of US stocks

Operating margin
11.5%

Higher than 68% of US stocks

Net margin
16.8%

Higher than 79% of US stocks

Returns & dividend
Return on equity
22.1%

Higher than 83% of US stocks

Return on assets
7.5%

Higher than 86% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Corcept Therapeutics, Inc. (CORT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Corcept Therapeutics, Inc. has a market value of $7.7B and an enterprise value of $7.3B.

  • Revenue in the twelve months to 30 June 2026: $830.8M. The latest quarter grew 64.0% year on year.

  • Net income over the same four quarters: $55.2M, a 6.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.42.

  • Free cash flow in the twelve months to 30 June 2026: $106.9M.

  • Shares outstanding: 107.9M.

  • Trailing P/E: 52.7×; forward P/E: 14.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Corcept Therapeutics, Inc. employs 730 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

CORT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CORTCorcept Therapeutics, Inc.$7.7B75
RYTMRhythm Pharmaceuticals, Inc.$7.4B84
CYTKCytokinetics, Inc.$7.4B61
CGONCG Oncology, Inc.$7.5B36
AXSMAxsome Therapeutics, Inc.$7.1B73
PTGXProtagonist Therapeutics, Inc.$8.0B89
TWSTTwist Bioscience Corp.$6.9B62

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Corcept Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CORT news & analysis

CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues

Zacks Investment Research · 4 Nov 2026positive

Corcept Therapeutics reported third-quarter earnings and revenue above estimates, with results driven by strong Lifyorli uptake and higher Korlym sales. The company is also advancing its pipeline.

Why it matters — CORT watchers may note the better-than-estimated quarterly results and the product sales contributing to revenue growth.

Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript

Seeking Alpha · 4 Nov 2026neutral

Seeking Alpha published a transcript of Corcept Therapeutics Incorporated’s Q3 2026 earnings call. The provided excerpt contains no details from the discussion.

Why it matters — The transcript is a source for CORT watchers, but the excerpt does not specify results or topics discussed.

Corcept Therapeutics Q3 Earnings Call Highlights

MarketBeat · 4 Nov 2026positive

Corcept Therapeutics reported third-quarter 2026 revenue of $340.5 million, up 33% from the prior quarter and 64% year over year. The company attributed growth to its endocrinology business and the launch of ovarian cancer treatment Lifyorli.

Why it matters — The reported revenue growth and stated business drivers provide CORT watchers with an update on the company’s recent results.

Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates

Zacks Investment Research · 3 Nov 2026positive

Corcept Therapeutics reported quarterly earnings of $1.01 per share, above the Zacks Consensus Estimate of $0.68. That compares with earnings of $0.16 per share a year earlier.

Why it matters — CORT watchers may note that quarterly earnings exceeded the consensus estimate and were higher than a year ago.

FAQ

Frequently asked questions about CORT stock

What is the CORT stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Corcept Therapeutics, Inc. have a median 12-month price target of $164, with estimates ranging from $50 to $173. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CORT stock a buy right now?

Of the 5 analysts covering Corcept Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Corcept Therapeutics, Inc. 75 out of 100 across roughly 4,600 US stocks as at 16 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CORT?

As at 16 Nov 2026, Corcept Therapeutics, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).

Will CORT stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +134.1% from the last close, and Ticker Nerd's factor model ranks Corcept Therapeutics, Inc. 75 out of 100 as at 16 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CORT stock forecast for 2030?

No analyst covering Corcept Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CORT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $173 over the next 12 months.

How has CORT stock performed over the past year?

Corcept Therapeutics, Inc. returned -6.7% over the 12 months to 17 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Corcept Therapeutics, Inc. do?

Corcept Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that modulate cortisol activity to address serious endocrine, oncologic, metabolic, and neurologic disorders.

What is the latest news on CORT?

The most recent item we track (Business Wire, 16 Nov 2026): "ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer". Corcept announced that ESMO Rare Cancers published a peer-reviewed case report describing an approximately eight-year response to relacorilant plus nab-paclitaxel in a patient with metastatic vulvar cancer.

Company

About Corcept Therapeutics, Inc.

Corcept Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that modulate cortisol activity to address serious endocrine, oncologic, metabolic, and neurologic disorders. Its commercial portfolio is centered on Korlym, an oral therapy used for adults with endogenous Cushing’s syndrome and related hypercortisolism. The company also advances a pipeline of selective cortisol modulators across multiple therapeutic areas, including relacorilant for Cushing’s syndrome and certain cancers, Lifyorli for oncology, and other investigational programs in metabolic disease and amyotrophic lateral sclerosis. Corcept Therapeutics serves the specialized rare-disease and specialty-pharmaceutical markets, where its products and research are aimed at conditions with limited treatment options. The company is headquartered in Redwood City, California.

CEO Dr. Joseph K. Belanoff M.D. · 730 employees · United States · https://www.corcept.com